Milestone Pharmaceuticals Inc. MIST
0.41 USD +0.05 (+13.21%)
Regular-session close
0.41 0.00 -0.77%
Pre-market · Nov 18, 4:07 AM ET
0.38 Day range 0.4586
0.362 52-week range 3.06
- YTD
- -79.54%
- 1 year
- -82.85%
News
benzinga.com Milestone Pharmaceuticals Analysts Cut Their Forecasts Following Q3 Results Milestone Pharmaceuticals (NASDAQ:MIST) on Friday reported a wider net loss for the third quarter and announced cost-cutting measures.
benzinga.com Milestone Pharmaceuticals Analysts Cut Their Forecasts Following Q3 Results Milestone Pharmaceuticals posted a wider loss but beat estimates, announced cost cuts, and saw shares fall 14.4% as analysts lowered price targets.benzinga.com TD Cowen Maintains Buy on Milestone Pharmaceuticals, Lowers Price Target to $5 TD Cowen analyst Ritu Baral maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and lowers the price target from $8 to $5.
benzinga.com Piper Sandler Maintains Overweight on Milestone Pharmaceuticals, Lowers Price Target to $3 Piper Sandler analyst Edward Tenthoff maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight and lowers the price target from $7 to $3.
benzinga.com HC Wainwright & Co. Maintains Buy on Milestone Pharmaceuticals, Lowers Price Target to $6 HC Wainwright & Co. analyst Brandon Folkes maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and lowers the price target from $8 to $6.
seekingalpha.com Milestone Pharmaceuticals Inc. (MIST) Q3 2026 Earnings Call Transcript Milestone Pharmaceuticals Inc. (MIST) Q3 2026 Earnings Call Transcript
marketbeat.com Milestone Pharmaceuticals Q3 Earnings Call Highlights Milestone Pharmaceuticals NASDAQ: MIST plans to cut operating expenses by approximately 30% as it seeks to extend its cash runway while building sales of CARDAMYST and advancing a late-stage clinical…
zacks.com Milestone Pharmaceuticals (MIST) Reports Q3 Loss, Beats Revenue Estimates Milestone Pharmaceuticals (MIST) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.12 per share a year ago.benzinga.com Milestone Pharmaceuticals Announces Cost-Efficiency Measures To Reduce Its Opex By ~30%, Completed By Q1 2027; Expects To Incur ~$2M In One-Time Charges Key elements of the cost-efficiency measures include:Bringing the sales force in-house: the Company plans to retain the existing field sales team of approximately 45 dedicated representatives,…
globenewswire.com Milestone Pharmaceuticals Reports Third Quarter 2026 Financial Results and Announces Cost-Efficiency Measures Designed to Extend Cash Runway Through AFib-RVR Phase 3 Data Launch of CARDAMYST ® (etripamil) nasal spray marked by steady prescription growth, new prescriber expansion and improving commercial coveragebenzinga.com Milestone Pharmaceuticals Q3 EPS $(0.18) Beats $(0.21) Estimate, Sales $2.963M Beat $1.143M Estimate Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.21) by 14.29 percent. This is a 50 percent decrease over losses…
